Masayuki Maeda

Dr. Masayuki Maeda

Division of Infection Control Sciences, Department of Clinical Pharmacy, School of Pharmacy, Showa University, Tokyo, Japan
orcid

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2018 in American Journal of Infection Control
Verified
Journal Article
Open access
HHHaruka Hattori
Haruka Hattori
MMMasayuki Maeda
Masayuki Maeda
YNYasuhiro Nagatomo
Yasuhiro Nagatomo
TTTakahiro Takuma
Takahiro Takuma
YNYoshihito Niki
Yoshihito Niki
KIKeiko Ishino
Keiko Ishino
Few published data are available on the morbidity and mortality of bloodstream infections (BSIs) in Japan. We sought to investigate the epidemiology of BSIs, the involvement of antimicrobial resistance, and the factors that influence patient prognosis. This single-center study retrospectively evaluated patients who were found to have positive blood cultures at a tertiary teaching hospital between January 2012 and December 2016. A total of 2,105 patients with BSIs were included; 1,786 survived and 319 died, and the 30-day mortality rate was 15.2% over the 5-year study period. BSIs caused by yeasts were independently associated with 30-day mortality. The 30-day mortality rate of BSIs caused by extended-spectrum beta lactamase-producing gram-negative bacteria was significantly higher than that of BSIs caused by nonproducing bacteria. The differences in mortality may be caused by differences in the distribution of pathogens and in the delivery of health care. This study reported epidemiology and antimicrobial resistance data of BSIs in Japan and identified several risk factors associated with 30-day mortality. National surveillance of BSIs is required in Japan for comparison with other countries.

1 February 2019 in Journal of Infection and Chemotherapy
Verified
Journal Article
Open access
MMMasayuki Maeda
Masayuki Maeda
YMYuichi Muraki
Yuichi Muraki
TKTadashi Kosaka
Tadashi Kosaka
TYTakehiro Yamada
Takehiro Yamada
YAYosuke Aoki
Yosuke Aoki
YNYoshihito Niki
Yoshihito Niki

1 September 2019 in Journal of Infection and Chemotherapy
Verified
Journal Article
Closed access
MMMasayuki Maeda
Masayuki Maeda
YMYuichi Muraki
Yuichi Muraki
TKTadashi Kosaka
Tadashi Kosaka
TYTakehiro Yamada
Takehiro Yamada
YAYosuke Aoki
Yosuke Aoki
TKTatsuya Kawaguchi
Tatsuya Kawaguchi

1 February 2016 in Journal of Infection and Chemotherapy
Verified
Journal Article
Closed access
MMMasayuki Maeda
Masayuki Maeda
TTTakahiro Takuma
Takahiro Takuma
HSHaruka Seki
Haruka Seki
KUKazuhisa Ugajin
Kazuhisa Ugajin
YNYuika Naito
Yuika Naito
YNYoshihito Niki
Yoshihito Niki

1 January 2021 in Journal of Infection and Chemotherapy
Verified
Journal Article
Closed access
MMMasayuki Maeda
Masayuki Maeda
YMYuichi Muraki
Yuichi Muraki
TKTadashi Kosaka
Tadashi Kosaka
TYTakehiro Yamada
Takehiro Yamada
YAYosuke Aoki
Yosuke Aoki
TKTatsuya Kawaguchi
Tatsuya Kawaguchi

7 September 2020 in International Journal Of Clinical Practice
Verified
Journal Article
Open access
PDF file
ASAyako Suzuki
Ayako Suzuki
MMMasayuki Maeda
Masayuki Maeda
TYTakuya Yokoe
Takuya Yokoe
MHMiyuki Hashiguchi
Miyuki Hashiguchi
MTMayumi Togashi
Mayumi Togashi
KIKeiko Ishino
Keiko Ishino
Background As a result of the constant increase in carbapenem resistance amongst gram‐negative bacteria in several countries, the inappropriate use of carbapenems must be reduced. Antimicrobial stewardship programmes (ASPs) aim to improve carbapenem usage by implementing interventions, including the promotion of the de‐escalation (DE) strategy. Thus, this study aimed to evaluate the impact of this strategy on carbapenem use based on a clear definition of DE. Methods The post‐prescription review and feedback (PPRF) strategy, which is used to optimise carbapenem use, was implemented by the antimicrobial stewardship team (AST). We compared the DE rate during the pre‐AST intervention period (from April 2017 to March 2018) and post‐AST intervention period (from April 2018 to March 2019). Result A total of 1500 patients (n = 771 in the pre‐AST intervention period and n = 729 in the intervention post‐AST period) were admitted to the hospital. The average duration of antibiotic therapy decreased from 9.9 to 7.7 days. The DE rate significantly increased in the post‐AST intervention period compared with the pre‐AST intervention period (51.4% vs 40.3%; P < .001). Conclusion The PPRF strategy implemented by the AST could improve the carbapenem usage by increasing the DE rate of carbapenem.